Biological Products, (No Diagnostic Substances)
Standard Industrial Classification: SIC 2836
Industry Insider Sentiment Analysis
The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-06 22:51 | 2026-04-02 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | SELL | $17.10 | 849,257 | $14,518,983 | 4,555,741 |
| 2026-04-06 21:39 | 2026-04-01 | BEAM | Beam Therapeutics Inc. | Bellon Christine | Officer | SELL | $24.58 | 5,956 | $146,398 | 109,711 |
| 2026-04-06 21:39 | 2026-04-01 | BEAM | Beam Therapeutics Inc. | Cavanagh Bethany J | Officer | SELL | $24.58 | 3,242 | $79,688 | 51,171 |
| 2026-04-06 21:44 | 2026-04-01 | BEAM | Beam Therapeutics Inc. | Simon Amy | Officer | SELL | $24.58 | 6,700 | $164,686 | 102,735 |
| 2026-04-06 21:48 | 2026-04-01 | BEAM | Beam Therapeutics Inc. | Evans John M. | Director, Officer | SELL | $24.58 | 30,078 | $739,317 | 1,047,205 |
| 2026-04-06 21:34 | 2026-04-01 | BEAM | Beam Therapeutics Inc. | Ciaramella Giuseppe | Officer | SELL | $24.58 | 11,810 | $290,290 | 218,406 |
| 2026-04-06 21:01 | 2026-04-02 | PTHS | Pelthos Therapeutics Inc. | Greenleaf Peter | Director | SELL | $20.92 | 797 | $16,670 | 24,681 |
| 2026-04-06 21:02 | 2026-04-02 | PTHS | Pelthos Therapeutics Inc. | Pauls Matthew | Director | SELL | $20.92 | 786 | $16,440 | 15,150 |
| 2026-04-06 21:03 | 2026-04-02 | PTHS | Pelthos Therapeutics Inc. | Friedberg Ezra M | Director | SELL | $20.92 | 558 | $11,671 | 82,027 |
| 2026-04-06 21:03 | 2026-04-02 | PTHS | Pelthos Therapeutics Inc. | Malamut Richard | Director | SELL | $20.92 | 590 | $12,340 | 27,422 |
| 2026-04-06 20:30 | 2026-04-02 | REPL | Replimune Group, Inc. | Sarchi Christopher | Officer | SELL | $8.01 | 6,500 | $52,065 | 151,588 |
| 2026-04-06 20:05 | 2026-04-02 | VCEL | Vericel Corp | Hopper Jonathan Mark | Officer | OPT+S | $35.00 | 3,472 | $121,520 | 75,556 |
| 2026-04-03 20:24 | 2026-04-01 | TECX | Tectonic Therapeutic, Inc. | Ruddy Marcella K. | Officer | SELL | $31.05 | 1,000 | $31,050 | 68,747 |
| 2026-04-03 20:00 | 2026-04-01 | TWST | Twist Bioscience Corp | Starovasnik Melissa A. | Director | SELL | $51.00 | 1,000 | $51,000 | 25,722 |
| 2026-04-04 00:00 | 2026-04-01 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | Officer | SELL | $85.01 | 2,000 | $170,020 | 177,371 |
| 2026-04-04 00:00 | 2026-04-01 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Officer | OPT+S | $84.84 | 5,500 | $466,619 | 208,398 |
| 2026-04-03 21:55 | 2026-04-02 | VYGR | Voyager Therapeutics, Inc. | Sandrock Alfred | Director, Officer | SELL | $3.87 | 11,511 | $44,548 | 472,549 |
| 2026-04-03 20:33 | 2026-04-02 | IMVT | Immunovant, Inc. | Venker Eric | Director, Officer | OPT+S | $24.10 | 14,229 | $342,855 | 19,561 |
| 2026-04-03 20:06 | 2026-04-01 | PCVX | Vaxcyte, Inc. | Wassil Jim | Officer | SELL | $58.43 | 2,250 | $131,476 | 162,994 |
| 2026-04-03 11:29 | 2026-04-01 | CGEN | COMPUGEN LTD | Ophir Eran | Director, Officer | OPT+S | $2.21 | 5,625 | $12,413 | 11,375 |
| 2026-04-03 11:31 | 2026-04-01 | CGEN | COMPUGEN LTD | Levine Zurit | Officer | OPT+S | $2.20 | 3,500 | $7,700 | 29,375 |
| 2026-04-02 20:06 | 2026-04-01 | MAZE | Maze Therapeutics, Inc. | Bachrodt Amy | Officer | OPT+S | $29.44 | 2,500 | $73,611 | 12,965 |
| 2026-04-02 20:08 | 2026-04-01 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Officer | OPT+S | $29.46 | 15,000 | $441,905 | 0 |
| 2026-04-02 20:47 | 2026-03-31 | ALLO | Allogene Therapeutics, Inc. | Beneski Benjamin Machinas | Officer | SELL | $2.50 | 2,867 | $7,168 | 195,338 |
| 2026-04-03 00:26 | 2026-04-02 | KOD | Kodiak Sciences Inc. | BORGESON JOHN A. | Officer | OPT+S | $39.92 | 30,000 | $1,197,489 | 183,316 |
| 2026-04-02 23:16 | 2026-04-01 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer | OPT+S | $14.53 | 38,120 | $553,693 | 447,202 |
| 2026-04-02 22:28 | 2026-04-01 | HALO | HALOZYME THERAPEUTICS, INC. | Torley Helen | Director, Officer | OPT+S | $64.81 | 40,000 | $2,592,236 | 767,780 |
| 2026-04-02 20:05 | 2026-04-01 | TARA | Protara Therapeutics, Inc. | Zummo Jacqueline | Officer | SELL | $5.26 | 22,598 | $118,865 | 95,961 |
| 2026-04-02 20:05 | 2026-04-01 | FENC | FENNEC PHARMACEUTICALS INC. | Raykov Rosty | Director | OPT+S | $6.31 | 10,946 | $69,069 | 113,856 |
| 2026-04-02 14:46 | 2026-04-01 | VIR | Vir Biotechnology, Inc. | SATO VICKI L | Director | SELL | $9.07 | 22,000 | $199,617 | 1,100,391 |
| 2026-04-01 20:12 | 2026-03-30 | MAZE | Maze Therapeutics, Inc. | Dandekar Atul | Officer | OPT+S | $29.34 | 7,500 | $220,019 | 10,503 |
| 2026-04-01 23:00 | 2026-03-31 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | Officer | OPT+S | $85.43 | 22,240 | $1,900,048 | 61,202 |
| 2026-04-01 23:00 | 2026-03-31 | KYMR | Kymera Therapeutics, Inc. | Ridloff Elena | Director | OPT+S | $85.39 | 12,000 | $1,024,661 | 0 |
| 2026-04-01 22:32 | 2026-03-30 | BEAM | Beam Therapeutics Inc. | Evans John M. | Director, Officer | OPT+S | $22.57 | 50,000 | $1,128,315 | 986,667 |
| 2026-04-01 11:51 | 2026-03-31 | CRIS | CURIS INC | KAITIN KENNETH I | Director | BUY | $0.55 | 10,000 | $5,487 | 11,407 |
| 2026-03-31 22:56 | 2026-03-27 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer | OPT+S | $13.14 | 57,180 | $751,305 | 455,878 |
| 2026-03-31 20:05 | 2026-03-27 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | BUY | $5.06 | 11,850 | $60,019 | 2,471,850 |
| 2026-03-30 21:59 | 2026-03-27 | GILD | GILEAD SCIENCES, INC. | O'Day Daniel Patrick | Director, Officer | SELL | $136.82 | 10,000 | $1,368,162 | 642,567 |
| 2026-03-30 22:04 | 2026-03-26 | CGEN | COMPUGEN LTD | Levine Zurit | Officer | OPT+S | $2.04 | 11,875 | $24,187 | 29,375 |
| 2026-03-30 21:29 | 2026-03-26 | SLXN | Silexion Therapeutics Corp | Shirvan Mitchell | Officer | SELL | $1.36 | 22,818 | $31,032 | 27,889 |
| 2026-03-30 12:46 | 2026-03-27 | LENZ | LENZ Therapeutics, Inc. | Chevallard Daniel R. | Officer | BUY | $8.57 | 7,500 | $64,275 | 12,886 |
| 2026-03-30 12:46 | 2026-03-27 | LENZ | LENZ Therapeutics, Inc. | Schimmelpennink Evert B. | Director, Officer | BUY | $8.95 | 28,089 | $251,411 | 77,289 |
| 2026-03-30 12:47 | 2026-03-27 | LENZ | LENZ Therapeutics, Inc. | George Jeffrey P. | Director | BUY | $8.92 | 5,592 | $49,890 | 5,592 |
| 2026-03-28 00:00 | 2026-03-25 | APGE | Apogee Therapeutics, Inc. | Henderson Jane | Officer | SELL | $85.00 | 2,000 | $170,000 | 179,371 |
| 2026-03-27 00:04 | 2026-03-25 | RVMD | Revolution Medicines, Inc. | Mancini Anthony | Officer | OPT+S | $95.56 | 37,450 | $3,578,819 | 54,400 |
| 2026-03-27 00:05 | 2026-03-24 | BCDA | BioCardia, Inc. | Altman Peter | Director, Officer | BUY | $1.23 | 900 | $1,110 | 274,766 |
| 2026-03-26 23:41 | 2026-03-24 | ADPT | Adaptive Biotechnologies Corp | RUBINSTEIN JULIE | Officer | OPT+S | $14.03 | 57,180 | $802,235 | 468,892 |
| 2026-03-26 22:57 | 2026-03-24 | ACOG | Alpha Cognition Inc. | Opaleye Management Inc. | 10% owner | BUY | $5.41 | 20,082 | $108,632 | 2,460,000 |
| 2026-03-26 00:02 | 2026-03-23 | SRZN | Surrozen, Inc./DE | TCG Crossover GP II, LLC | 10% owner | BUY | $24.72 | 121,881 | $3,012,764 | 736,547 |
| 2026-03-25 21:15 | 2026-03-23 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | Officer | OPT+S | $78.02 | 115,977 | $9,048,294 | 61,202 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Biological Products, (No Diagnostic Substances)
Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.